Open Access
BIOGRAPHICAL
H. Magdelénat, J. Rouessé
Oncologie, Vol.21, No.1, pp. 1-2, 2019, DOI:10.3166/onco-2019-0022
Abstract This article has no abstract. More >
Open Access
EDITORIAL
A. Lesur, F. Guillemin
Oncologie, Vol.21, No.1, pp. 3-4, 2019, DOI:10.3166/onco-2019-0032
Abstract This article has no abstract. More >
Open Access
ARTICLE
S. Dejust
Oncologie, Vol.21, No.1, pp. 5-10, 2019, DOI:10.3166/onco-2019-0031
Abstract Axillary evaluation is a major step in the initial
staging of breast cancer. Ultrasound guided biopsy is currently recommended in first-line. MRI and 18FDG PET/CT
are useful in axillary lymph node evaluation. Imaging sensitivities and specificities are globally identical and their combination allows obtaining the best performances. Currently,
sentinel node technique is essential in case of T1-T2 N0
mammary tumors and in case of suspected lymph node adenopathy with negative cytopuncture or microbiopsy.
Résumé
L’exploration préthérapeutique axillaire est une
étape majeure du bilan initial du cancer du sein. L’échographie associée à un prélèvement est actuellement recommandée en première intention. L’IRM et la… More >
Open Access
ARTICLE
J. Boudier, G. Oldrini, C. Barlier, A. Lesur
Oncologie, Vol.21, No.1, pp. 11-16, 2019, DOI:10.3166/onco-2019-0034
Abstract When a breast cancer is diagnosed, the quality of
the evaluation before treatment is essential to guide the therapeutic decision. The staging axillary is necessary because
it estimates the regional extension of the disease, which
makes it a paramount prognosis factor. Some different preoperative medical imaging can reveal metastasis axillary
nodes. However, the axillary ultrasound remains the reference imaging and it also leads the biopsies too. Since
theACOSOG-Z0011 trial, we are facing a therapeutic deescalation in the axillary surgery. According to recent
results, we can note that the position of the axillary imaging
is more and more important. The purpose… More >
Open Access
ARTICLE
G. Oldrini, P. Henrot, F. Marchal
Oncologie, Vol.21, No.1, pp. 17-21, 2019, DOI:10.3166/onco-2019-0033
Abstract Breast cancer is the first female cancer in France
and its early detection is essential. Breast MRI is an element
of choice in its diagnosis but it has high direct and indirect
costs because of its duration which slows down its wider use.
Given its elements, the use of an abbreviated protocol develops to overcome these disadvantages. Early literature data
suggests that this faster examination also allows for a shorter
interpretation time. In addition, the sensitivity and specificity
of the examination are not inferior to that of the complete
protocol. This article explains the new concept and its interest, compares… More >
Open Access
ARTICLE
F. Guillemin, F. Marchal, M. Geffroy
Oncologie, Vol.21, No.1, pp. 22-28, 2019, DOI:10.3166/onco-2019-0028
Abstract Purpose: Assessment of a second surgical conservative treatment (T) [N = 41] compared to total mastectomy
(M) [N = 93] for ipsilateral breast tumor recurrence after initial breast conserving surgery in a retrospective study of
134 patients.
Results: Five years global survival was 82.5% in each group.
No statistical difference for the specific survival and survival
without metastasis. The 5 years local control was 92.9% in
group M and 66.2% in group T (RR = 4.48). Lymphovascular invasion (LVI), multifocal tumors, and clinical symptoms
of the recurrence are pejorative factors for survival. Over the
134 patients, 25 have preserved their… More >
Open Access
ARTICLE
V. Massard, A. Harlé, L. Uwer, J.-L. Merlin
Oncologie, Vol.21, No.1, pp. 29-32, 2019, DOI:10.3166/onco-2019-0027
Abstract Acquired endocrine resistance remains one of the
main obstacles in the treatment of estrogen receptor (ER)
positive, HER2 negative advanced breast cancer. Recently,
activating ESR1 gene mutations affecting the ligand-binding
domain have been identified as a key mechanism in aromatase
inhibitor (AI) resistance. These mutations can be detected on
histological samples or circulating tumour DNA, using PCRbased assays or next-generation sequencing. They induce a
constitutive activation of ER, leading to acquired resistance
to AI; tamoxifen, fulvestrant and targeted therapies against
mTOR or CDK4/6 retain their efficacy. The use of monitoring
ESR1 mutations in clinical practice is still to be defined.… More >
Open Access
ARTICLE
A. de Nonneville, A. Gonçalves
Oncologie, Vol.21, No.1, pp. 33-39, 2019, DOI:10.3166/onco-2019-0039
Abstract Triple-negative breast cancer (TNBC), defined by
the lack of expression of hormone receptors and HER2
(Human Epidermal growth factor Receptor-2), accounts for
15–20% of breast cancers. However, this definition, which is
essentially negative, masks the large biological heterogeneity of this subtype. While chemotherapy is the main established systemic treatment in both early and advanced stages
of the disease, the progressive understanding of the molecular components involved in the pathogenesis of TNBC
allows innovative therapeutic perspectives. The objective
of this review is to describe these potential targets and to
explore current and future treatments that will help fighting
this cancer with… More >
Open Access
ARTICLE
V. Allouchery, L. Augusto, F. Clatot
Oncologie, Vol.21, No.1, pp. 40-48, 2019, DOI:10.3166/onco-2019-0035
Abstract It has been known for a long time that circulating
tumor cells (CTC) as well as circulating tumor DNA (ctDNA)
can be detected. However, only recent technical advances
allowed evaluating the interest of CTC and ctDNA in breast
cancer. In both early and metastatic breast cancers, CTC
detection is a recognized factor for poor outcome. Nevertheless, CTC detection does not impact cancer management yet.
The use of ctDNA in daily practice will require validation by
prospective data. But ctDNA seems particularly promising
both for residual disease evaluation and identification of
tumor clones harbouring mutations (PI3KC, ESR1) and
may predict efficacy… More >
Open Access
EDITORIAL
D. Grazziotin-Soares, J.-P. Lotz
Oncologie, Vol.21, No.1, pp. 49-51, 2019, DOI:10.3166/onco-2019-0037
Abstract This article has no abstract. More >
Open Access
ARTICLE
T. Pudlarz, N. Naoun, G. Beinse, D. Grazziotin-Soares, J.-P. Lot
Oncologie, Vol.21, No.1, pp. 53-68, 2019, DOI:10.3166/onco-2019-0036
Abstract In this special issue of Oncology, we have summarized the most relevant topics that were presented at the
American Association for Cancer Research (AACR) meeting. Our purpose here is to give the readers a concise report
of the presentations that warrant particular attention. This
year 2019 in Atlanta, the AACR Annual Meeting program
covered the latest discoveries across the spectrum of cancer
research — from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy — and highlights the work of the best
minds in research and medicine from institutions all over
the world. It… More >
Open Access
ARTICLE
D. Grazziotin-Soares, J.-P. Lotz
Oncologie, Vol.21, No.1, pp. 69-72, 2019, DOI:10.3166/onco-2019-0030
Abstract Several studies have shown an association between Epstein-Barr virus (EBV) infection and some human
cancers such as a subgroup of gastric carcinomas. The oncogenic potential of EBV has been widely explored but the
exact processes conducting carcinogenesis are not yet fully
understood. EBV-encoded viral proteins are known to deregulate the DNA damage response (DDR) signaling pathways. DDR inactivation leads to genomic instability and
promote cellular transformation to generate malignant cells.
In a recently published article in Nature Medicine, a molecular characterization of tumor tissue and circulating tumor
DNA (cDNA) from non-selected patients with metastatic
gastric cancer treated with pembrolizumab was… More >
Login
Register
Submit a Paper
Propose a Special lssue